Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFILE-D phase III study of oral LPRI-CF113 versus dienogest in dysmenorrhea
jRCT2031260648Phase 3Recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dysmenorrhea comparing LPRI-CF113 arm with Dienogest control arm (2 arms). Primary endpoint: Change from baseline in dysmenorrhea score during the third menstrual cycle after administration of study drug. Planned start Dec 2026; status: recruiting.
02
Drugs
LPRI-CF113dienogest
03
Conditions
dysmenorrhea
Beyond the preview
Go deeper on jRCT2031260648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260648.